Research work · 2017

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas C. C. Yau

The Lancet

Read free full text

DOI: 10.1016/s0140-6736(17)31046-2